125 related articles for article (PubMed ID: 27843642)
1. ASCO highlights podcast: head and neck cancers.
Merlano M
ESMO Open; 2016; 1(5):e000099. PubMed ID: 27843642
[TBL] [Abstract][Full Text] [Related]
2. [Radiotherapeutic studies of head and neck cancer-highlights of the 2018 ASCO Annual Meeting].
Ott S; Wiegel T; Laban S; Hoffmann TK; Petersen C; Tribius S
HNO; 2018 Dec; 66(12):901-906. PubMed ID: 30421001
[TBL] [Abstract][Full Text] [Related]
3. [Studies on radiotherapy of head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Ott S; Wiegel T; Hoffmann TK; Petersen C; Tribius S; Laban S
HNO; 2019 Dec; 67(12):918-924. PubMed ID: 31659379
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy highlights of the ASCO annual meeting 2018 for head and neck cancers].
Laban S; Doescher J; Busch CJ; Wollenberg B; Dietz A; Würdemann N; Schuler PJ; Hoffmann TK
HNO; 2018 Dec; 66(12):880-887. PubMed ID: 30402813
[TBL] [Abstract][Full Text] [Related]
5. Highlights in breast cancer from ASCO 2016.
Cardoso F
ESMO Open; 2016; 1(5):e000106. PubMed ID: 27900208
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
8. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
9. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
10. Overview of combined modality therapies for head and neck cancer.
Dimery IW; Hong WK
J Natl Cancer Inst; 1993 Jan; 85(2):95-111. PubMed ID: 8418313
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study).
Zenda S; Ota Y; Kiyota N; Okano S; Fujii M; Kitamura M; Takahashi S; Ueda T; Monden N; Yamanaka T; Tahara M
Front Oncol; 2019; 9():6. PubMed ID: 30723701
[No Abstract] [Full Text] [Related]
12. [Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Doescher J; Busch CJ; Wollenberg B; Dietz A; Würdemann N; Schuler P; Hoffmann TK; Laban S
HNO; 2019 Dec; 67(12):905-911. PubMed ID: 31612261
[TBL] [Abstract][Full Text] [Related]
13. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
14. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
15. Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types).
Nouman M; Haider G; Bukhari N; Yousuf A; Nouman R; Shaikh MR; Hussain S; Pavan B; Rahool R; Memon P; Zahoor S; Mehar K; Sami A
Asian Pac J Cancer Prev; 2020 Mar; 21(3):825-830. PubMed ID: 32212813
[TBL] [Abstract][Full Text] [Related]
16. [Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
Gliese A; Busch CJ; Knecht R
HNO; 2016 Oct; 64(10):717-22. PubMed ID: 27624903
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
Klinghammer K; Gauler T; Dietz A; Grünwald V; Stöhlmacher J; Knipping S; Schroeder M; Guntinas-Lichius O; Frickhofen N; Lindeman HW; Fietkau R; Haxel B; Große-Thie C; Maschmeyer G; Zipfel M; Martus P; Knoedler M; Keilholz U
Eur J Cancer; 2019 Nov; 122():53-60. PubMed ID: 31618704
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Forastiere AA; Metch B; Schuller DE; Ensley JF; Hutchins LF; Triozzi P; Kish JA; McClure S; VonFeldt E; Williamson SK
J Clin Oncol; 1992 Aug; 10(8):1245-51. PubMed ID: 1634913
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
20. Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Li J; Merl MY; Chabot J; Saif MW
JOP; 2010 Jul; 11(4):310-2. PubMed ID: 20601799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
